Research ArticleClinical Studies

Management of Patients With Metastatic Renal Cell Cancer and Bone Metastases

CARSTEN NIEDER, ASTRID DALHAUG and ADAM R. PAWINSKI
In Vivo March 2020, 34 (2) 675-678; DOI: https://doi.org/10.21873/invivo.11822

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Actuarial overall survival of patients with bone metastases at the time of systemic first-line treatment (early, n=26) and patients with bone metastases later during the course of the disease (delayed, n=9). Their median survival is 13 and 46 months, respectively (p=0.01).

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Management of Patients With Metastatic Renal Cell Cancer and Bone Metastases
CARSTEN NIEDER, ASTRID DALHAUG, ADAM R. PAWINSKI
In Vivo Mar 2020, 34 (2) 675-678; DOI: 10.21873/invivo.11822
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords